Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-10-23
2007-10-23
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C514S012200, C530S324000
Reexamination Certificate
active
11162817
ABSTRACT:
The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.
REFERENCES:
patent: 5639725 (1997-06-01), O'Reily et al.
patent: 5801012 (1998-09-01), Soff et al.
patent: 5801146 (1998-09-01), Davidson
patent: 5945403 (1999-08-01), Folkman et al.
patent: 6743428 (2004-06-01), Chang et al.
patent: 7118905 (2006-10-01), Chang et al.
patent: WO 2004/073730 (2004-09-01), None
Mikol V, et al., 1996, Crystal structures of apolipoprotein(a) kringle IV37 free and complexed with 6-aminohexanoic acid and with p-aminomethylebenzoid acid: existence of novel and expected binding modes. J Mol Biol. 256(4):751-61.
Burgess et al., 1990, Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding growth factor-1 from its receptor-binding activites by site-directed mutagenesis of a single lysine residue. J Cell Biol. 111:2129-2138.
Bowie Ju et al., 1990, Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science. 247 (4948):1306-1310.
Fogarty M., 2002, Learning from Angiogenesis Trial Failures. The Scientist 16:33.
Fan TP et al., 1995, Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci. 16:57-66.
Wallace RW, 1998, Media hype and drug discovery Drug Discovery Today, 3(10):433-434.
Cao Y et al., 1997, Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 272:22924-22928.
Kraft HG et al., 1995, Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the aopolipoprotein (a) size polymorphism Hum Genet. 95(3):275-282.
McLean et al., 1987, cDNA sequence of human apolipoprotein(a) is homologous to plaminogen. Nature 330(6144):132-7.
Lou, X. J. et al., 1998, Despite Its Homology to Angiostatin Apolipoprotein(a) Does Not Affect Angiogenesis, Exp. Mol. Pathol., 65:53-63.
LoGrasso, P. V. et al., 1994, Cloning, Expression, and Characterization of Human Apolipoprotein (a) Kringle IV37, J. Biol. Chem., 269(34):21820-21827.
Scanu, A. M. and Edelstein, C., 1994, Apolipoprotein(a): structural and functional consequences of mutations in kringle type 10 (or kringle 4-37), Clinical Genetics, 46:42-45.
Scanu, A. M. et al., 1994, A single point mutation (Trp 72 {dot over (a)} Arg) in human apo (a) kringle 4-37 associated with a lysine binding defect in Lp(a), Biochimica et Biophysica Acta, 1227:41-45.
Gabel, B. R. and Koschinsky, M. L., 1998, Sequences within Apolipoprotein(a) Kringle IV Types 6-8 Bind Directly to Low-Density Lipoprotein and Mediate Noncovalent Assocation of Apolipoprotein(a) and Apolipoprotein B-100, Biochemistry, 37:7892-7898.
Ahn Jin-Hyung
Kim Jang-Seong
Lee Ho-Jeong
Park Doo-Hong
Yoon Yeup
Haddad Maher M.
JHK Law
Kim Joseph Hyosuk
Mogam Biotechnology Research Institute
LandOfFree
Anticancer agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3831828